Results 121 to 130 of about 98,461 (251)

Sudden Death Due to Association between NAFLD and Cardiovascular Changes in a 37-Year-Old Man: a Case Report

Acta Medica Iranica, 2016
Fatty liver disease (FLD) is the most prevalent form of liver disease worldwide. Overnutrition can induce nonalcoholic fatty liver disease (NAFLD), a spectrum of conditions ranging from simple steatosis [or nonalcoholic fatty liver (NAFL)] to ...
Maryam Ameri, Shahrokh Mehrpisheh, Azadeh Memarian, Payam Balvayeh   +3 more
doaj  

Esteatohepatite não alcoólica.

Acta Médica Portuguesa, 1995
The authors present a case of a nonalcoholic steatohepatitis, with progression to liver cirrhosis in an obese female patient. A review of the literature, possible evolution, and principle pathological processes involved is made.
P M da Silva, T Eliseu, M M Costa, H Bastos, F L Nobre   +4 more
doaj   +1 more source

Hepatic Macrophages Express Melanoma Differentiation-Associated Gene 5 in Nonalcoholic Steatohepatitis [PDF]

, 2021
Shogo Kawaguchi, Hirotake Sakuraba, Momone Horiuchi, Jiangli Ding, Tomoh Matsumiya, Kazuhiko Seya, Chikara Iino, Tetsu Endo, Hidezumi Kikuchi, Shukuko Yoshida, Hiroto Hiraga, Shinsaku Fukuda, Tadaatsu Imaizumi   +12 more
openalex   +1 more source

Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Given the high prevalence of the population who have metabolic dysfunction‐associated steatohepatitis (MASH), interest is growing in MASH‐targeted treatments. However, currently, there has been only one regulatory approved drug for MASH (Rezdiffra).
Quyen Thi Tran, Tham Thi Bui, Lien Thi Ngo, Bo Ram Yang, In‐Hwan Baek, Van Hung Nguyen, Kyung Ae Lee, Hwi‐yeol Yun, Jung‐woo Chae, Soyoung Lee, Jae Hyun Kim, Woojin Jung   +11 more
wiley   +1 more source

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

Phytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes [PDF]

, 2020
Kenneth Cusi
openalex   +1 more source

Hepatic fibrosis in patients diagnosed with rheumatoid arthritis and psoriatic arthritis receiving methotrexate: A cross‐sectional analysis using transient elastography

Rheumatology &Autoimmunity, EarlyView.
Hepatic fibrosis and metabolic syndrome are more prevalent in PsA patients treated with methotrexate, compared to RA patients. Metabolic syndrome is associated with the risk of hepatic fibrosis in patients diagnosed with PsA and RA even after adjustment forcumulative methotrexate exposure.
Ratchaya Lertnawapan, Soonthorn Chonprasertsuk, Sith Siramolpiwat, Kanon Jatuworapruk   +3 more
wiley   +1 more source

Exploration of Multiple Non‐Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH

Alimentary Pharmacology &Therapeutics, EarlyView.
This study investigated multiple non‐invasive tests (NIT) in a phase 2b study of patients with MASH and fibrosis treated with semaglutide. Findings revealed that semaglutide significantly improved NIT scores versus placebo from as early as 28 weeks. The results support the use of NITs to assess a treatment response to semaglutide.
Louise Maymann Nitze, Vlad Ratziu, Arun J. Sanyal, Vincent Wai‐Sun Wong, Clare Balendran, Jan Fleckner, Mette Skalshøi Kjær, Niels Krarup, Quentin M. Anstee   +8 more
wiley   +1 more source

Narcolepsy Is Associated With Subclinical Cardiovascular Disease as Early as Childhood: A Big Data Analysis

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Narcolepsy is linked to adverse cardiovascular disease (CVD) outcomes, but few studies have examined its associations with subclinical CVD, including in children.
Christopher N. Kaufmann, Munaza Riaz, Haesuk Park, Wei‐Hsuan Lo‐Ciganic, Debbie Wilson, Emerson M. Wickwire, Atul Malhotra, Rakesh Bhattacharjee   +7 more
doaj   +1 more source

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO‐NASH Trial

Alimentary Pharmacology &Therapeutics, EarlyView.
This secondary analysis of the MAESTRO‐NASH trial examined the effects of resmetirom in patients with weight loss and/or treated with therapies for T2D. The efficacy of resmetirom was not impacted by background T2DM therapies. Weight loss (≥ 5%) enhanced the effect of resmetirom on multiple MASH endpoints. ABSTRACT Background MAESTRO‐NASH, a randomised,
Mazen Noureddin, Mary Rinella, Rebecca Taub, Dominic Labriola, Raul C. Camacho, Naim Alkhouri, Rohit Loomba, Meena B. Bansal   +7 more
wiley   +1 more source